MOLECULAR DOCKING STUDIES OF FLAVONOIDS AGAINST DRIVER MARKERS IN LOW-GRADE GLIOMA: EXPLORING NOVEL THERAPEUTIC APPROACHES

Low-grade gliomas (LGGs) are a group of slow-growing brain tumors that often exhibit long-term survival in patients. However, the lack of effective therapeutic strategies and the eventual progression to high-grade gliomas pose significant clinical challenges. Driver markers, such as IDH1, TP53, and ATRX mutations, play pivotal roles in the molecular pathogenesis of LGGs. Flavonoids, a group of polyphenolic compounds found in fruits and vegetables, have been recognized for their potential anticancer properties. In this study, we employed molecular docking to evaluate the binding affinities of flavonoids against IDH1, a key driver marker in LGG. Our results demonstrate that certain flavonoids exhibit strong binding interactions with the active site of IDH1, suggesting their potential as novel therapeutic agents for LGG. This study provides insights into the development of flavonoid-based therapies targeting driver markers in LGG.